Lead Bookrunner on INOVIO Pharmaceuticals' Registered Direct Offering

INOVIO Pharmaceuticals, Inc. (Nasdaq: INO) (the “Company”), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer and infectious diseases, announced the pricing of an underwritten offering of 2,536,258 shares of its common stock at an offering price of $7.693 per share and pre-funded warrants to purchase 2,135,477 shares of its common stock at an offering price of $7.692 per pre-funded warrant. Gross proceeds to INOVIO from the offering were $35,937,522, before deducting underwriting discounts and commissions and estimated offering expenses payable by INOVIO. The offering was led by Deep Track Capital.

The Company intends to use the net proceeds from this offering for the development of its clinical pipeline including clinical development and pre-commercialization expenses relating to INO-3107, clinical development expenses relating to a planned clinical trial of INO-3112, research and development expenses for its earlier-stage programs and for general corporate purposes including working capital and general and administrative expenses.